Efficacy, Safety and Quality of Life with different Itraconazole regimens in Recurrent Tinea Corporis and Tinea Cruris: An Interventional Study

Pt BD Sharma PGIMS Rohtak0 个研究点目标入组 72 人开始时间: 待定最近更新: 2023年2月6日

试验速览

暂无简介。

•1. Patient 18-65 years of age of either gender
•2. Patient who has recurrence of lesions of tinea corporis and tinea cruris in less than 6 weeks after clinical cure
•3. Patient willing to provide written informed consent.
•4. Patients willing to come for regular follow up.

•1. Patient who has recurrence of lesions of tinea corporis and tinea cruris in less than 6 weeks after completion of treatment with Itraconazole and having been cured clinically.
•2. Patient suffering from tinea infections other than tinea corporis and tinea cruris.
•3. Patients with a history of intolerance or hypersensitivity to the study drugs.
•4. Patients who have serious concomitant illness which can prevent the completion of study.
•5. Patients with contact dermatitis, atopic dermatitis, psoriasis or any other skin disease.
•6. All pregnant and breastfeeding females.
•7. Patients with hepatic, renal or cardiac disease.
•8. Patients on drugs that are contraindicated for use with itraconazole, which include pimozide, dofetilide, quinidine, oral midazolam, triazolam, nisoldipine, felodipine, dihydroergotamine, ergotamine, ergometrine, methylergometrine, cisapride, lovastatin, simvastatin, levacetylmethadol, and methadone.

发起方

Pt BD Sharma PGIMS Rohtak